Carmot Therapeutics, Inc.
Clinical trials sponsored by Carmot Therapeutics, Inc., explained in plain language.
-
New drug shows promise for diabetes and weight loss in early trial
Disease control CompletedThis study tested an experimental drug called CT-868 in 103 overweight or obese adults with type 2 diabetes. The goal was to see if the drug could lower blood sugar levels and help with weight loss over 26 weeks. Participants received either the drug or a placebo, and researchers…
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 07:57 UTC
-
New weekly shot shows promise for obesity weight loss in major trial
Disease control CompletedThis study tested a new weekly injection called CT-388 to help people with obesity or overweight lose weight. About 469 adults took part, receiving either a low, middle, or high dose of the drug or a placebo for 48 weeks. The main goal was to see how much weight they lost and if …
Phase: PHASE2 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New injection shows promise for obesity and diabetes
Disease control CompletedThis early-stage study tested an experimental drug called CT-388 in 129 overweight or obese adults, some with type 2 diabetes. The goal was to check safety and how the drug affects body weight and blood sugar. Participants received either the drug or a placebo as a shot under the…
Phase: PHASE1 • Sponsor: Carmot Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC